Minerva Neurosciences (NERV) 10-K2024 FY Annual report

Filed: 25 Feb 25, 6:30am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: Biopharma, bipolar, Bristol, campaign, Caplyta, closer, Cobenfy, CODM, concomitantly, Council, CRL, daily, Denovo, deviation, electrocardiogram, erosion, female, fifteen, foresaw, fringe, hearing, laid, lumateperone, Luye, muscarinic, older, parliament, partnership, relaunching, remeasurement, retrospective, retrospectively, Russian, sequelae, serialization, shifting, Trump

Removed: abandoned, argued, assistance, Avanir, ceased, challenge, correspondingly, defensive, derive, digital, dismissed, disposed, economy, entirety, EP, estimation, foreseen, heading, incomplete, intrinsic, methodology, President, proportionate, prospectively, qualitative, quantitative, recommended, repealed, Roche, Takeda, transferred, unconstitutional, USD

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NERV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement Nos. 333-267424 and 333-273686 on Form S-3 and Nos. 333-242460, 333-225672, 333-223593, 333-222368, 333-216637, 333-210147, 333-203738, and 333-198753 on Form S-8 of our report dated February 25, 2025, relating to the financial statements of Minerva Neurosciences, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2024.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

February 25, 2025

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.